19th Annual International Myeloma Society Meeting
Doris Hansen, MD, of the Moffitt Cancer Center, spoke about the research during an oral abstract presentation at IMS. Adding a monoclonal antibody to a triplet treatment significantly lowered the risk of disease... A single infusion of ciltacabtagene autoleucel “resulted in deep and durable responses" in CARTITUDE-2’s cohort A. The data were from the phase III DETERMINATION trial... Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over... Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...